2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1529

Upper Airway Gene Expression Profiling in Granulomatosis with Polyangiitis
Abstract Number: 2065

Uptake of the American College of Rheumatology’s (ACR) Rheumatology Clinical Registry (RCR): Quality Measure Summary Data
Abstract Number: 2397

Urinary Biomarkers in Vasculitis Associated with Anti-Neutrophil Cytoplasmic Antibodies
Abstract Number: 628

Urinary Heparanase Activity Is Elevated in Patients with Lupus Nephritis and Correlate with Protein Excretion
Abstract Number: 839

Urinary Levels of High Mobility Group Box 1 Protein Are Elevated in Patients with Active Lupus Nephritis, and Correlate with Renal Histopathology
Abstract Number: 2474

Urine Biomarkers Distinguish Between Proliferative and Membranous Lupus Nephritis in Childhood Onset Systemic Lupus Erythematosus
Abstract Number: 2388

Urticarial Vasculitis: Clinical Study
Abstract Number: 114

US Examination of Wrists and Hands: A Comparison Between Rheumatoid Arthritis and Psoriatic Arthritis
Abstract Number: 2234

US Treatment Patterns of Psoriatic Arthritis Patients Newly Initiated On Etanercept or Adalimumab
Abstract Number: 377

Use and Long Term Use of Complementary and Alternative Medicine in Rheumatoid Arthritis Patients
Abstract Number: 526

Use of a Novel Probe to Demonstrate Granzyme B Activity in Sjogren’s Syndrome Salivary Glands
Abstract Number: 378

Use of Anti-Tumor Necrosis Factor Monotherapy and Adherence with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs in Combination with Anti-Tumor Necrosis Factor Therapy Among Rheumatoid Arthritis Patients in a Real-World Setting
Abstract Number: 1242

Use of Anti-Tumor Necrosis Factor Therapy Is Associated with Reduced Cardiovascular Event Risk in Rheumatoid Arthritis
Abstract Number: 270

Use of Drug Combinations in Patients with Osteoarthritis: A Population-Based Cohort Study
Abstract Number: 523

Use of Global Gene Expression Profiling to Characterize Sjögren’s Patients Who Underexpress Interferon-Inducible Genes

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].